MediWound Ltd.

Good day, and welcome to the Meadowoon First Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your question, please press star then two. Please note today's event is being recorded. I'd now like to turn the conference over to Dan Ferry of LifeSci Advisors. Please go ahead.

Thank you, Operator, and welcome, everyone. Earlier today, pre-market open, MediWood issued a press release announcing financial results for the first quarter ended March 31, 2026. You may access this press release on the company's website under the Investors tab. I would ask you to review the full text of our forward-looking statements within this morning's press release. Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session, relating to MediWN's expected future performance, future business prospects, or future events or plans are forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from expectations and are described more fully in our filings with the SEC. In addition, All forward-looking statements represent our views only as of today, and MetaWound assumes no obligation to update or supplement any forward-looking statements, whether a result of new information, future events, or otherwise. This conference call is the property of MetaWound, and any recording or rebroadcast is expressly prohibited without the written consent of MetaWound. With us today are Ofer Gonan, Chief Executive Officer of MetaWound, and Hani Luxemburg, Chief Financial Officer. Barry Wolfensohn, EVP of Strategy and Corporate Development, is also participating in today's call. Following our prepared remarks, we will open the call for Q&A. Now, I would like to turn the call over to Ofer Gonen, Chief Executive Officer of Meadowood.

Ofer? Thank you, Dan, and good morning, everyone. During the first quarter of 2026, we continued to execute against our key strategic priorities, advancing S-correction. towards commercialization and expanding the global role of NexoBridge. While the timeline for SCRx Phase III value study has shifted by one quarter, the underlying momentum behind the program continues to strengthen. During this quarter, we expanded our chronic wound collaboration network, generated additional clinical and scientific validation for both SCRx and NexoBridge, and continue to see strong engagement from strategic collaborators and the broader wound care community. We continue to advance our expanded NexoBrit manufacturing facility toward commercial readiness and further strengthen long-term opportunities with industry leaders and government partners across our portfolio. Let me start with an update on Escarex. Enrollment continues in the global Phase III value study in venous leg ulcers with more than 30 sites active across the United States, Europe, and Israel. Recruitment has progressed more gradually than originally anticipated, primarily due to two operational factors. First, certain European sites required ancillary related regulatory adjustments, which have been now completed, and we expect the study to reach the targeted 40 active sites within weeks. Second, The travel and visit requirements associated with the protocol created participation challenges for the older and medically complex VLU patient population. To support enrollment and reduce participation burden, we implemented patient assistance measures, including hotel reimbursements, transportation services, and facilitated access to enhanced care. Importantly, given how quickly Escarex works, The protocol requires daily wound assessments to determine the exact day complete debridement is achieved. This represents a shift from measuring debridement outcomes over weeks. While this creates operational complexity in the study, it may ultimately reflect one of SCRx's key clinical and commercial advantages in real-world practice. Investigator engagement and site participation remain strong across all regions, and we expect the interim sample size reassessment and the enrollment completion by the end of the first quarter of 2027. At the same time, we continue to see expanding commercial, clinical, and scientific validation supporting the broader opportunity of Escarex across the chronic wound care market. Medline, a global leader in medical, surgical, and wound care products, has joined our collaboration network. Together with Coloplast Keresis, Convatec, Essity, Malneka, Solventum, B. Brown, and MyMedix, our collaborators now include essentially all the major advanced wound care companies relevant to the program. As part of the collaboration, Medline will provide its class-leading skin protectant, Marathon, for the upcoming DFU Phase II study. Marathon is designed to protect tissue surrounding the wound, while escarex performed its debridement activity within the wound bed. A peer-reviewed U.S. expert consensus document published in Wound Journal emphasized the need for effective, easy-to-use, and less invasive debridement approaches in chronic wound care, a conclusion that aligns closely with the clinical profile and positioning of escarex. We also presented new clinical data and new preclinical data at the WHS, SAWC, and NUMA conferences, highlighting escorex's clinical benefits, distinct mechanism of action, and broad potential across venous leg ulcers, diabetic foot ulcers, and pressure ulcers. Turning to Nexobrid. During the quarter, we continue to see growing commercial adoption, clinical recognition, and strategic interest in Nexobrid across both traditional burn care settings and government preparedness initiatives. VeriCell reported continued growth in both ordering centers and total orders across the United States burn care market, reflecting ongoing adoption trends. Most importantly, VeriCell was also awarded a 10-year BARDA contract valued at up to $197 million to support next-row procurement, vendor management inventory services, potential blast trauma indication development, and next-generation manufacturing and formulation capabilities. We expect BARDA-related procurement and development to begin during the second half of 2026. This new 10-year BARDA contract builds on approximately $138 million already received from BARDA and the Department of War over the past decade, further solidifying the significance of NexoBREAD as a strategic asset in mass casualty burn response and national preparedness. Importantly, the burn care community continues to move in the same direction. Newly published national consensus guidelines from Japan and the UK now added to existing recommendation from the WHO and countries including Italy, Spain, Romania, and Poland. To support this global demand, we remain focused on bringing our expanding manufacturing facility online. We are implementing modifications identified during a recent EMA pre-audit, and we expect to complete those implementations activities during the second half of 2026. With that, I'll turn on the call to Hani.